Compare ALUR & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | LSTA |
|---|---|---|
| Founded | 2009 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Misc Health and Biotechnology Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 16.4M |
| IPO Year | N/A | N/A |
| Metric | ALUR | LSTA |
|---|---|---|
| Price | $1.48 | $4.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.25 | ★ $15.00 |
| AVG Volume (30 Days) | 109.6K | ★ 357.6K |
| Earning Date | 11-12-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.02 | $1.81 |
| 52 Week High | $7.40 | $4.89 |
| Indicator | ALUR | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 89.72 |
| Support Level | $1.28 | $2.05 |
| Resistance Level | $1.57 | $4.89 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | -0.03 | 0.27 |
| Stochastic Oscillator | 32.31 | 89.78 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.